The Lancet Haematology/X
Jun 13, 2025, 23:21
Paul J Bröckelmann Shares The Lancet Haematology Commission Update on Adverse Events at EHA 2025
The Lancet Haematology shared a post on X:
“Today at EHA2025 Dr Paul J Bröckelmann shared insights from The Lancet Haematology Commission on Adverse Events.
Our 2025 Series updates priority areas on measuring and managing toxicities in new haematology treatment.”
Paul J Bröckelmann presented updates from The Lancet Haematology Commission’s 2025 Series at EHA 2025, focusing on improving how adverse events are measured and managed in modern haematology therapies.
You Can Find More Posts on Hemostasis Today.
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: Don’t Let EDTA Fool You – When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis
-
Jun 23, 2026, 22:32How WFH Impacted the Bleeding Disorders Community in 2025
-
Jun 23, 2026, 19:20Simos Kokkovos: 1st Ever Mobile Stroke Unit in Greece is on its way to Metropolitan Hospital
-
Jun 23, 2026, 18:27Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jun 23, 2026, 18:17What Every ITP Patient Wants to Know – ITP Support Association
-
Jun 23, 2026, 18:13Ahsan Fareed: Exploring Heart Failure Readmissions in Iron Deficiency Anemia
-
Jun 23, 2026, 18:09Swarnava Roy: Key Findings on Stress Erythropoiesis and Mitochondrial Retention in RBCs